We describe the case of a 73-year-old man who experienced dry cough and exertional dyspnea after dabigatran administration. Chest radiographs revealed the development of bilateral consolidative and ground glass opacity, and transbronchial lung biopsy showed organized materials in the alveolar spaces with moderate inflammatory infiltrate and focal fibrosis. Lung opacity gradually disappeared after discontinuing dabigatran. To date, there has been only one report regarding dabigatran-induced lung injury, except for alveolar hemorrhage and eosinophilic pneumonia. Therefore, we should consider that any drug can cause various types of lung injuries.
Introduction
With the ever-increasing number of therapeutic drugs, the list of drugs responsible for severe pulmonary diseases also increases. Druginduced lung injury is defined as a lung injury that results from the specific use of a drug associated with various types of lung complication, including organizing pneumonia (OP). Here we describe a case of bilateral consolidation and ground glass opacity observed on chest radiograph after administering dabigatran, a novel anticoagulant.
Case report
A 73-year-old man with a history of chronic heart failure, paroxysmal atrial fibrillation, and a 24-month treatment regime of dabigatran was referred to our department because of his dry cough and exertional dyspnea (modified MRC grade 2). Examination of the patient's respiratory system revealed fine crackles at the lower back. Chest X-ray showed bilateral infiltration in the lower field, and chest high-resolution computed tomography (HRCT) showed nonsegmental subpleural consolidation and ground glass opacity, indicating nonspecific interstitial pneumonia (NSIP) with OP pattern (Fig. 1 ). Blood tests revealed elevated KL-6 levels (1302 U/mL) and slightly elevated eosinophil percentage with no anemia. No autoantibodies were observed (Table 1) .
Bronchoscopy was performed to evaluate the patient's progress after discontinuing dabigatran. Bronchoalveolar lavage fluid (BALF) was not bloody, and cell fractionation revealed 71.5% macrophages, 8.0% neutrophils, 17.7% lymphocytes, and 2.8% eosinophils. The CD4/CD8 ratio of lymphocytes in BALF was 1.81. Microbiological examination results of BALF revealed no evidence of infection. Transbronchial lung biopsy specimen suggested OP (Fig. 2) .
After bronchoscopy, we administered warfarin instead of dabigatran. Two months later, the patient's symptoms such as dry cough and dyspnea completely disappeared, and chest HRCT revealed that the lung infiltration had also disappeared ( Fig. 1 ). Six months later, serum KL-6 levels reduced to normal levels. Therefore, the patient's interstitial pneumonia was diagnosed to be a drug-induced lung injury caused by dabigatran.
Discussion
Drug-induced lung injury is diagnosed on the basis of clinical examination and radiographic and histological findings [1] . Cases that develop subacutely, as in the present case, tend to be NSIP or OP. Although we have not conducted a drug-induced lymphocyte stimulation test for dabigatran, the patient's pathological findings and clinical course corresponded with the diagnosis of OP.
Dabigatran is a relatively new anticoagulant agent from the direct thrombin inhibitor class. Dabigatran is preferred to warfarin in many cases because it offers similar efficacy with a lower risk for bleeding and does not require frequent blood tests [2] . However, few cases of alveolar hemorrhage [3, 4] , eosinophilic pneumonia [5] , and OP [6] have been reported as adverse events. In the present case, the patient had no symptoms or findings of alveolar hemorrhage. In 2011, the Ministry of Health, Labour and Welfare of Japan issued an alert that dabigatran administration might be associated with interstitial lung diseases, including death in cases with preexisting interstitial pneumonia. Thus, this is well recognized in Japan at least but only one case report of interstitial pneumonia has been published. Physicians should be aware of any potential adverse effects, including drug-induced lung injury, associated with novel drugs.
